51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
44 citations
,
April 2019 in “Journal of the American Academy of Dermatology” Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
21 citations
,
October 2017 in “Journal of the European Academy of Dermatology and Venereology” Various potential triggers may be causing the rise in frontal fibrosing alopecia, and avoiding these could help stop the disease's increase.
20 citations
,
March 1990 in “JAMA” Topical eye β-blockers may cause hair loss.
17 citations
,
June 2024 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata significantly affects mental health, especially in women and those with severe cases.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
15 citations
,
January 2015 in “Skin Appendage Disorders” Increased scalp sweating in frontal fibrosing alopecia may be linked to local skin inflammation.
12 citations
,
October 2016 in “Anais Brasileiros de Dermatologia” Frontal Fibrosing Alopecia may be linked to autoimmune diseases like Sjögren's syndrome.
11 citations
,
March 2021 in “Dermatology and therapy” Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.
9 citations
,
July 2020 in “Journal of Dermatology” Asian patients with Frontal Fibrosing Alopecia often lose eyebrow hair and respond well to combined antiandrogen or antimalarial and topical treatments.
9 citations
,
August 2018 in “Journal der Deutschen Dermatologischen Gesellschaft” Most patients with frontal fibrosing alopecia are middle-aged women, often have thyroid disease, and some treatments can help stabilize the condition.
8 citations
,
October 2005 in “Otolaryngologic Clinics of North America” The document concludes that successful management of eyebrow and forehead ptosis requires a thorough approach, considering anatomy, patient evaluation, and careful selection of surgical techniques.
6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
6 citations
,
September 2014 in “Cutaneous and ocular toxicology” Acitretin can cause eyebrow and eyelash hair loss.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
3 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The main goal for new Alopecia Areata treatments should be significant improvement in scalp hair growth.
2 citations
,
July 2025 in “Advances in Therapy” Alopecia areata negatively impacts quality of life and work, even with moderate hair loss.
2 citations
,
June 2021 in “Sultan Qaboos University medical journal” Familial frontal fibrosing alopecia is rare, mostly affects women, and often occurs between sisters or mother-daughter pairs.
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
1 citations
,
May 2022 in “British Journal of Dermatology” The instruments are valid but don't fully capture the emotional impact on adolescents with alopecia areata.
1 citations
,
September 2021 in “CRC Press eBooks” Frontal Fibrosing Alopecia is a hair loss condition mainly affecting postmenopausal women, with unclear causes and various clinical patterns.
February 2026 in “Reports — Medical Cases Images and Videos” Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
December 2025 in “JEADV Clinical Practice” A woman with hair loss condition experienced rare hair color return, suggesting it might help diagnose the condition.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
October 2025 in “Indian Dermatology Online Journal” Cultural practices can influence trichotillomania, requiring culturally sensitive treatment.
August 2025 in “American Journal of Clinical Dermatology” Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.